Journal of Clinical Oncology
Articles in this Issue
Innovative diagnostic approaches: Serum protein markers in renal cell carcinoma.
560 Background: In the era of precision medicine, we pursue less invasive, more powerful methods for screening, response prediction, and recurrence detect...
Surveillance with plasma ctDNA in non-muscle invasive bladder cancer.
864 Background: Non-muscle invasive bladder cancer (NMIBC), constitutes 70% of all bladder cancer. Routine surveillance methods for detecting patients at...
Decipher genomic classifier (DGC) of early prostate cancer (EPC), and underlying transcriptomic profile (TP): American (Am) versus non-American (NA).
414 Background: Data on DGC in EPC, come predominantly from US patients (pts), revealing significant reclassification of NCCN risk Despite its global use,...
Do tissue-based biomarkers in metastatic clear cell renal cell carcinoma perform better when derived from a metastatic site?
569 Background: Gene expression and mutation analyses in metastatic clear cell renal cell carcinoma (ccRCCs) have attempted to identify tumors that differ...
The comparison of clinical utility between pan-cancer panel and PCa-specific panel for mCRPC.
47 Background: To compare the diagnostic efficiency of pathogenic variants and the value for clinical decision making between a pan-cancer panel and a pro...
Carcinoma of prostate sequencing of tumor and clinical endpoints (CAPSTONE): Clinical implications of recurrent genomic alterations in lethal prostate cancer.
220 Background: Prostate cancer (PC) is genetically heterogeneous, and genomic alterations may impact prognosis and therapy response. We created CAPSTONE,...
Long-term safety outcomes of <sup>177</sup> Lu-PSMA-617 in patients with prostate cancer.
TPS294 Background: Approval of [ 177 Lu]Lu-PSMA-617 ( 177 Lu-PSMA-617) for the treatment of adult patients...
Comorbidity burden and effectiveness of immunotherapy in patients with metastatic renal cell carcinoma.
509 Background: Comorbidities pose a challenge in the treatment of patients with cancer and present a barrier to inclusion in clinical trials. While the e...
Estimation of overall survival in immunotherapy-treated bladder cancer using computer vision.
862 Background: Bladder cancer (BC) is a difficult and expensive cancer to treat, as lifelong care is needed. Anti-PD-1 therapies are used as a frontline...
NEXUS-01, a phase 1 study of LY4052031, an antibody-drug conjugate targeting Nectin-4 in participants with advanced or metastatic urothelial carcinoma or other solid tumors.
TPS900 Background: Nectin-4 is a cell surface antigen overexpressed in multiple tumor types including urothelial cancer. Enfortumab vedotin (EV) is a firs...
Contemporary post-prostatectomy radiation therapy for prostate cancer within a statewide quality consortium.
369 Background: The 2024 AUA Salvage Therapy for Prostate Cancer Guideline provides guidance at the time of suspected recurrence after radical prostatecto...
Non-clear cell renal cell carcinoma in the immune checkpoint era: A retrospective study on survival and treatment approaches.
512 Background: Non-clear cell renal cell carcinoma (nccRCC) includes several molecularly distinct subtypes of renal carcinoma. Due to their rarity, nccRC...
Socioeconomic position as a social determinant of health and its effect on cardiovascular outcomes and mortality in patients with prostate cancer: A SEER-Medicare based study.
315 Background: Socioeconomic position (SEP) is a key social determinant of health (SDOH) associated with disparities in cancer care and cardiovascular (C...
Expression of tissue factor (TF) in penile squamous cell carcinoma (PSCC) and enrichment in HPV-negative cases.
10 Background: Advanced/metastatic PSCC is an aggressive malignancy with limited treatment options. An antibody-drug conjugate (ADC) targeting TF is appro...
Results of AFU-GETUG-20: A randomised phase 3 trial of adjuvant androgen deprivation therapy with leuprorelin acetate after radical prostatectomy in patients with high-risk localized prostate cancer.
386 Background: After radical prostatectomy (RP), men with an undetectable PSA and specific features (extracapsular extens...
Peri-operative treatment patterns in real-world muscle-invasive bladder cancer patients undergoing radical cystectomy in the era of adjuvant immunotherapy.
704 Background: Muscle-invasive bladder cancer (MIBC) has traditionally been managed with radical cystectomy (RC) and pelvic lymph node dissection combine...
Effectiveness and safety of first-line atezolizumab in locally advanced or metastatic urothelial cancer: The IMFLAME study.
720 Background: Urothelial cancer (UC) is the tenth most common cancer globally. Standard first-line treatment for metastatic UC (mUC) involves enfotumab-...
Survival in advanced prostate cancer (PCa) patients with visceral metastasis: A population-based SEER study.
134 Background: Prostate cancer patients with visceral metastases at diagnosis are often treated using one-size-fits-all approach. For example, CHAARTED c...
Predictive value of neoadjuvant therapy combined with VI-RADS re-scoring in bladder preservation for muscle-invasive bladder cancer.
688 Background: Radical cystectomy (RC) is standard treatment for muscle-invasive bladder cancer (MIBC). However, many pat...
Use of urinary cell-free DNA fragmentomics in urothelial carcinoma diagnosis.
846 Background: Traditional diagnostic procedures for urothelial carcinoma (UC) are often limited by patient burden and reduced sensitivity, impacting dia...
Head-to-head comparison of micro-ultrasound, mpMRI, and PSMA PET/CT with a wholemount histopathology as gold standard in the detection and T staging of prostate cancer.
338 Background: Micro-Ultrasound (MicroUS) is a new imaging modality capable of identifying prostate cancer (PCa). Prior evaluation of MicroUS and multipa...
Comparison of IO-TKI vs IO-IO combinations in IMDC poor-risk metastatic renal cell carcinoma (mRCC) patients (Meet-URO 33 analysis).
495 Background: Immune-combinations have become the cornerstone of the mRCC treatment landscape, but head-to-head comparisons between the different first-...
Transdermal oestradiol (tE2) patches as androgen deprivation therapy (ADT): Efficacy and safety of combining with androgen receptor pathway inhibitors (ARPIs) in metastatic (M1) prostate cancer—Randomised comparison from the STAMPEDE trial platform.
21 Background: Recent phase III data (n=1360) has shown that starting ADT with tE2 patches is non-inferior in terms of metastasis-free survival (with simi...
OCTOPUS: A retrospective, multicenter study of real-world cabozantinib treatment of patients with advanced renal cell carcinoma in France—Subgroup analyses of treatment sequences and optimization.
472 Background: Cabozantinib is an established therapy for advanced renal cell carcinoma (aRCC) in France. We evaluated real-world data from the OCTOPUS s...
Implementing Indiana regimen salvage high-dose chemotherapy in relapsed germ cell tumors in Slovakia.
642 Background: Salvage chemotherapy for relapsed testicular germ cell tumors (GCT) remains controversial, however, large retrospective series show higher...